本研究採隨機、雙盲、有安慰劑對照的並行試驗，招募90位45-60歲停經早期、血清FSH大於40m IU/ml的健康婦女，隨機分兩組，一組為異黃酮加鈣組(n = 62)，每天早晚空腹服用兩次黃豆異黃酮 (120mg/d) 與鈣 (560 mg/d)，另一組為鈣組 (n = 28) 服用同量安慰劑（無糖麵茶）與鈣。實驗前、服用3與6個月後收集血與尿。以尿液異黃酮排出量評估受試者配合度，並依尿液中是否有equol，將異黃酮加鈣組再區分為能產生equol者 (n = 31) 與不能產生equol者 (n = 31)。以Kupperman index評估更年期症狀改善之效果，雙光能吸收儀(DEXA)測量骨質密度，並比較血脂、C–reactive protein （CRP）、雌二醇（E2）、濾泡刺激素（FSH）、性激素結合蛋白（SHBG）、骨質合成指標-血清osteocalcin（OC），骨質分解指標C-telopeptide of type I collagen (CTX)，與尿液骨質分解指標deoxypyridinoline (DPD)。結果顯示，異黃酮加鈣組對Kupperman index的改善與安慰劑加鈣組無顯著差異，但其中能產生equol者補充異黃酮加鈣後，對臉部潮紅、容易疲倦及Kupperman index 總分的改善顯著較佳（p＜0.05）。血脂、CRP、FSH、LH、SHBG皆無顯著差異。異黃酮加鈣組E2顯著上升（p＜0.05），其中不能產生equol者的E2濃度顯著最高，且有顯著最低的DPD（p＜0.05）。安慰劑加鈣組的OC與DPD都顯著高於異黃酮加鈣組（p＜0.05），且腰椎骨及左、右臗關骨骨質密度顯著優於異黃酮加鈣組（p＜0.05）。綜上所述，補充鈣6個月使骨質轉換速率及骨密高於補充異黃酮加鈣；不能產生equol者補充異黃酮加鈣可顯著上升血清E2濃度且顯著下降骨質分解；能產生equol者補充異黃酮加鈣可顯著改善更年期症狀。故補充鈣或異黃酮加鈣對停經婦女各有不同的助益，個人是否能將異黃酮代謝產生equol也會影響異黃酮的功效。

參考文獻
【中文部分】
王天美。民92年。台灣地區婦女罹患骨質疏鬆症的流行病學研究：以台中市和和花蓮市為例。國民健康局。民94年10月22日，取自：http://www.bhp.doh.gov.tw

【英文部分】

Adlercreutz, H., Bannwart, C., Wahala, K., Makela, T., Brunow, G., Hase, T., et al. (1993). Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. The Journal of Steroid Biochemistry and Molecular Biology, 44(2), 147.
Adlercreutz, H., Honjo, H., Higashi, A., Fotsis, T., Hamalainen, E., Hasegawa, T., et al. (1991). Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr, 54(6), 1093-1100.
Akaza, H., Miyanaga, N., Takashima, N., Naito, S., Hirao, Y., Tsukamoto, T., et al. (2004). Comparisons of percent equol producers between prostate cancer patients and controls: Case-controlled studies of isoflavones in Japanese, korean and American residents. Jpn. J. Clin. Oncol., 34(2), 86-89.
Axelson, M., Kirk, D. N., Farrant, R. D., Cooley, G., Lawson, A. M., & Setchell, K. D. (1982). The identification of the weak oestrogen equol [7-hydroxy-3-(4'-hydroxyphenyl)chroman] in human urine. Biochem J, 201(2), 353-357.
Bacon, W. E. (1996). Secular trends in hip fracture occurrence and survival: Age and sex differences. J Aging Health, 8(4), 538-553.
Bassan, J., Frame, B., & Frost, H. (1963). Osteoporosis: A review of pathogenesis and treatment. Ann Intern Med, 58, 539-550.
Barnes, S., & Messina, M. (2002). Introduction and satellite session at the fourth international symposium on the role of soy in preventing and treating chronic disease. J. Nutr., 132(3), 545S-546.
Beecher, H. K. (1955). The powerful placebo. J Am Med Assoc, 159(17), 1602-1606.
B., Melkko, J., Risteli, L., & Risteli, J. (1990). Circulating c-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J, 271(2), 345-350.

Benvenuti, S., Tanini, A., Frediani, U., Bianchi, S., Masi, L., Casano, R., et al. (1991). Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line. J Bone Miner Res, 6(9), 987-996.
Black, D., Duncan, A., & Robins, S. P. (1988). Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem, 169(1), 197-203.
Black, D. M., Cummings, S. R., Genant, H. K., Nevitt, M. C., Palermo, L., & Browner, W. (1992). Axial and appendicular bone density predict fractures in older women. J Bone Miner Res, 7(6), 633-638.
Blair, H. C., Jordan, S. E., Peterson, T. G., & Barnes, S. (1996). Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem, 61(4), 629-637.
Bukowski, C., Grigg, M. A., & Longcope, C. (2000). Sex hormone-binding globulin concentration: Differences among commercially available methods. Clin Chem, 46(9), 1415-1416.
Brandi, M. L. (1992). Flavonoids: Biochemical effects and therapeutic applications. Bone Miner, 19 Suppl 1, S3-14.

Breitman, P. L., Fonseca, D., Cheung, A. M., & Ward, W. E. (2003). Isoflavones with supplemental calcium provide greater protection against the loss of bone mass and strength after ovariectomy compared to isoflavones alone. Bone, 33(4), 597-605.

Campbell, D. R., & Kurzer, M. S. (1993). Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J Steroid Biochem Mol Biol, 46(3), 381-388.

Chen, Z., Zheng, W., Custer, L. J., Dai, Q., Shu, X. O., Jin, F., et al. (1999). Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer, 33(1), 82-87.

Christiansen, C., Christensen, M. S., & Transbol, I. (1981). Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet, 1(8218), 459-461.

de Kleijn, M. J., van der Schouw, Y. T., Wilson, P. W., Adlercreutz, H., Mazur, W., Grobbee, D. E., et al. (2001). Intake of dietary phytoestrogens is low in postmenopausal women in the united states: The framingham study(1-4). J Nutr, 131(6), 1826-1832.
Duncan, A. M., Phipps, W. R., & Kurzer, M. S. (2003). Phyto-oestrogens. Best Pract Res Clin Endocrinol Metab, 17(2), 253-271.
Enmark, E., & Gustafsson, J. A. (1999). Oestrogen receptors - an overview. J Intern Med, 246(2), 133-138.
Epker, B. N. (1967). Bone remodeling and balance and the development of osteoporosis. Annu Meet Am Inst Oral Biol, 3-15.
Faulkner, K. G., von Stetten, E., & Miller, P. (1999). Discordance in patient classification using t-scores. J Clin Densitom, 2(3), 343-350.
Fonseca, D., & Ward, W. E. (2004). Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice. Bone, 35(2), 489-497.

Fujioka, M., Uehara, M., Wu, J., Adlercreutz, H., Suzuki, K., Kanazawa, K., et al. (2004). Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice. J Nutr, 134(10), 2623-2627.
Frankenfeld, C. L., Atkinson, C., Thomas, W. K., Goode, E. L., Gonzalez, A., Jokela, T., et al. (2004). Familial correlations, segregation analysis, and nongenetic correlates of soy isoflavone-metabolizing phenotypes. Exp Biol Med (Maywood), 229(9), 902-913.
Frankenfeld, C. L., McTiernan, A., Thomas, W. K., LaCroix, K., McVarish, L., Holt, V. L., et al. (2006). Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes. Maturitas, 53(3), 315-324.
Fu, S. Y., Anderson, D., & Courtney, M. (2003). Cross-cultural menopausal experience: Comparison of Australian and Taiwanese women. Nurs Health Sci, 5(1), 77-84.

Gabbitas, B., & Canalis, E. (1998). Insulin-like growth factors sustain insulin-like growth factor-binding protein-5 expression in osteoblasts. Am J Physiol, 275(2 Pt 1), E222-228.
Gao, Y. H., & Yamaguchi, M. (2000). Suppressive effect of genistein on rat bone osteoclasts: Involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J Mol Med, 5(3), 261-267.
Gilani, G. S., & J.B, J. (2002). Phytoestrogens and a health. Canda.

Garcia-Perez, M. A., Moreno-Mercer, J., Tarin, J. J., & Cano, A. (2003). Relationship between pth, sex steroid and bone turnover marker measurements and bone density in recently postmenopausal women. Maturitas, 45(1), 67-74.

Garnero, P. (2000). Markers of bone turnover for the prediction of fracture risk. Osteoporos Int, 11 Suppl 6, S55-65.
Garnero, P., Grimaux, M., Demiaux, B., Preaudat, C., Seguin, P., & Delmas, P. D. (1992). Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Miner Res, 7(12), 1389-1398.
Goldberg, M. P. (1965). Bone remodeling. Periodontics, 3(5), 248-252.
Hall, W. L., Vafeiadou, K., Hallund, J., Bugel, S., Reimann, M., Koebnick, C., et al. (2006). Soy-isoflavone-enriched foods and markers of lipid and glucose metabolism in postmenopausal women: Interactions with genotype and equol production. Am J Clin Nutr, 83(3), 592-600.
Haines, S. T., Caceres, B., & Yancey, L. (1996). Alternatives to estrogen replacement therapy for preventing osteoporosis. J Am Pharm Assoc (Wash), NS36(12), 707-715.
Hansen, M. A., Overgaard, K., Riis, B. J., & Christiansen, C. (1991). Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. Bmj, 303(6808), 961-964.
Hassager, C., Fabbri-Mabelli, G., & Christiansen, C. (1993). The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteoporos Int, 3(1), 50-52.
Heaney, R. P., Recker, R. R., & Saville, P. D. (1978). Menopausal changes in calcium balance performance. J Lab Clin Med, 92(6), 953-963.

Heaney, R. P., Weaver, C. M., & Fitzsimmons, M. L. (1991). Soybean phytate content: Effect on calcium absorption. Am J Clin Nutr, 53(3), 745-747.

Heaney, R. P., Dowell, M. S., Rafferty, K., & Bierman, J. (2000). Bioavailability of the calcium in fortified soy imitation milk, with some observations on method. Am J Clin Nutr, 71(5), 1166-1169.
Ho, S. C., Chan, S. G., Yip, Y. B., Cheng, A., Yi, Q., & Chan, C. (1999). Menopausal symptoms and symptom clustering in Chinese women. Maturitas, 33(3), 219-227.
Hsu, C. S., Shen, W. W., Hsueh, Y. M., & Yeh, S. L. (2001). Soy isoflavone supplementation in postmenopausal women. Effects on plasma lipids, antioxidant enzyme activities and bone density. J Reprod Med, 46(3), 221-226.
Hutchins, A. M., Slavin, J. L., & Lampe, J. W. (1995). Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc, 95(5), 545-551.
Ibbotson, K. J., Orcutt, C. M., D'Souza, S. M., Paddock, C. L., Arthur, J. A., Jankowsky, M. L., et al. (1992). Contrasting effects of parathyroid hormone and insulin-like growth factor i in an aged ovariectomized rat model of postmenopausal osteoporosis. J Bone Miner Res, 7(4), 425-432.
Jenkins, D. J., Kendall, C. W., Connelly, P. W., Jackson, C. J., Parker, T., Faulkner, D., et al. (2002). Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. Metabolism, 51(7), 919-924.
Jensen, C., Holloway, L., Block, G., Spiller, G., Gildengorin, G., Gunderson, E., et al. (2002). Long-term effects of nutrient intervention on markers of bone remodeling and calciotropic hormones in late-postmenopausal women. Am J Clin Nutr, 75(6), 1114-1120.
Johnston, C. C., Jr., & Slemenda, C. W. (1995). Identification of patients with low bone mass by single photon absorptiometry and single-energy x-ray absorptiometry. Am J Med, 98(2A), 37S-40S.
Kang, J. S., Yoon, Y. D., Han, M. H., Han, S. B., Lee, K., Kang, M. R., et al. (2005). Estrogen receptor-independent inhibition of tumor necrosis factor-alpha gene expression by phytoestrogen equol is mediated by blocking nuclear factor-kappab activation in mouse macrophages. Biochem Pharmacol, 71(1-2), 136-143.
Kanis, J. A., Melton, L. J., 3rd, Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994). The diagnosis of osteoporosis. J Bone Miner Res, 9(8), 1137-1141.
Kardinaal, A. F., Morton, M. S., Bruggemann-Rotgans, I. E., & van Beresteijn, E. C. (1998). Phyto-oestrogen excretion and rate of bone loss in postmenopausal women. Eur J Clin Nutr, 52(11), 850-855.
Karr, S. C., Lampe, J. W., Hutchins, A. M., & Slavin, J. L. (1997). Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. Am J Clin Nutr, 66(1), 46-51.

Kenney, M. A., McCoy, H., & Williams, L. (1994). Effects of magnesium deficiency on strength, mass, and composition of rat femur. Calcif Tissue Int, 54(1), 44-49.
Kirkman, L. M., Lampe, J. W., Campbell, D. R., Martini, M. C., & Slavin, J. L. (1995). Urinary lignan and isoflavonoid excretion in men and women consuming vegetable and soy diets. Nutr Cancer, 24(1), 1-12.
Krebs, E. E., Ensrud, K. E., MacDonald, R., & Wilt, T. J. (2004). Phytoestrogens for treatment of menopausal symptoms: A systematic review. Obstet Gynecol, 104(4), 824-836
Kiel, D. P., Felson, D. T., Anderson, J. J., Wilson, P. W., & Moskowitz, M. A. (1987). Hip fracture and the use of estrogens in postmenopausal women. The framingham study. N Engl J Med, 317(19), 1169-1174.
Keeting, P. E., Rifas, L., Harris, S. A., Colvard, D. S., Spelsberg, T. C., Peck, W. A., et al. (1991). Evidence for interleukin-1 beta production by cultured normal human osteoblast-like cells. J Bone Miner Res, 6(8), 827-833.
Kelly, G. E., Joannou, G. E., Reeder, A. Y., Nelson, C., & Waring, M. A. (1995). The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med, 208(1), 40-43.
Kikuchi, Y., Shimamura, Y., Hirokado, M., Yasuda, K., & Nishijima, M. (2001). [daily intake of isoflavones based on the market basket method]. Shokuhin Eiseigaku Zasshi, 42(2), 122-127.
Lampe, J. W., Karr, S. C., Hutchins, A. M., & Slavin, J. L. (1998). Urinary equol excretion with a soy challenge: Influence of habitual diet. Proc Soc Exp Biol Med, 217(3), 335-339.
Lau, E. M., Woo, J., Lam, V., & Hong, A. (2001). Milk supplementation of the diet of postmenopausal chinese women on a low calcium intake retards bone loss. J Bone Miner Res, 16(9), 1704-1709.
Levitz, M., Banerjee, S., Raju, U., Toniolo, P. G., Shore, R. E., & Nachtigall, L. E. (1997). Sex hormone-binding globulin in estrogen-dependent cancer and estrogen replacement therapy. Ann N Y Acad Sci, 828, 358-365.
Loukovaara, M., Carson, M., & Adlercreutz, H. (1995). Regulation of sex-hormone-binding globulin production by endogenous estrogens in vitro. Biochem Biophys Res Commun, 206(3), 895-901.

Lian, J. B., & Gundberg, C. M. (1988). Osteocalcin. Biochemical considerations and clinical applications. Clin Orthop Relat Res(226), 267-291.
Looker, A. C., Orwoll, E. S., Johnston, C. C., Jr., Lindsay, R. L., Wahner, H. W., Dunn, W. L., et al. (1997). Prevalence of low femoral bone density in older U.S. Adults from nhanes iii. J Bone Miner Res, 12(11), 1761-1768.
Lu, L. J., & Anderson, K. E. (1998). Sex and long-term soy diets affect the metabolism and excretion of soy isoflavones in humans. Am J Clin Nutr, 68(6 Suppl), 1500S-1504S.
Lydeking-Olsen, E., Beck-Jensen, J. E., Setchell, K. D., & Holm-Jensen, T. (2004). Soymilk or progesterone for prevention of bone loss--a 2 year randomized, placebo-controlled trial. Eur J Nutr, 43(4), 246-257.

Macdonald, H. M., New, S. A., Golden, M. H., Campbell, M. K., & Reid, D. M. (2004). Nutritional associations with bone loss during the menopausal transition: Evidence of a beneficial effect of calcium, alcohol, and fruit and vegetable nutrients and of a detrimental effect of fatty acids. Am J Clin Nutr, 79(1), 155-165.
Minkin, C. (1982). Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int, 34(3), 285-290.
Mendel, C. M. (1992). The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl, 13(2), 107-116.
Muthyala, R. S., Ju, Y. H., Sheng, S., Williams, L. D., Doerge, D. R., Katzenellenbogen, B. S., et al. (2004). Equol, a natural estrogenic metabolite from soy isoflavones: Convenient preparation and resolution of r- and s-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem, 12(6), 1559-1567.

Nicholls, J., Lasley, B. L., Nakajima, S. T., Setchell, K. D., & Schneeman, B. O. (2002). Effects of soy consumption on gonadotropin secretion and acute pituitary responses to gonadotropin-releasing hormone in women. J Nutr, 132(4), 708-714.
Pacifici, R. (1996). Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res, 11(8), 1043-1051.
Parfitt, A. M., Mathews, C. H., Villanueva, A. R., Kleerekoper, M., Frame, B., & Rao, D. S. (1983). Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest, 72(4), 1396-1409.
Picherit, C., Coxam, V., Bennetau-Pelissero, C., Kati-Coulibaly, S., Davicco, M.-J., Lebecque, P., et al. (2000). Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J. Nutr., 130(7), 1675-1681.
Podenphant, J., Johansen, J. S., Thomsen, K., Riis, B. J., Leth, A., & Christiansen, C. (1987). Bone turnover in spinal osteoporosis. J Bone Miner Res, 2(6), 497-503.
Potter, S. M., Baum, J. A., Teng, H., Stillman, R. J., Shay, N. F., & Erdman, J. W., Jr. (1998). Soy protein and isoflavones: Their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr, 68(6 Suppl), 1375S-1379S.
Ren, M. Q., Kuhn, G., Wegner, J., Nurnberg, G., Chen, J., & Ender, K. (2001). Feeding daidzein to late pregnant sows influences the estrogen receptor beta and type 1 insulin-like growth factor receptor mrna expression in newborn piglets. J Endocrinol, 170(1), 129-135.
Rich-Edwards, J. W., Manson, J. E., Hennekens, C. H., & Buring, J. E. (1995). The primary prevention of coronary heart disease in women. N Engl J Med, 332(26), 1758-1766.
Rickard, D., Russell, G., & Gowen, M. (1992). Oestradiol inhibits the release of tumour necrosis factor but not interleukin 6 from adult human osteoblasts in vitro. Osteoporos Int, 2(2), 94-102.
Ross, P. D. (1998). Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am, 27(2), 289-301.
Ross, P. D., Wasnich, R. D., & Vogel, J. M. (1988). Detection of prefracture spinal osteoporosis using bone mineral absorptiometry. J Bone Miner Res, 3(1), 1-11.

Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. Jama, 288(3), 321-333.
Rowland, I., Wiseman, H., Sanders, T., Adlercreutz, H., & Bowey, E. (1999). Metabolism of oestrogens and phytoestrogens: Role of the gut microflora. Biochem Soc Trans, 27(2), 304-308.
Rowland, I. R., Wiseman, H., Sanders, T. A., Adlercreutz, H., & Bowey, E. A. (2000).
Ricciotti, H. A., Khaodhiar, L., & Blackburn, G. L. (2005). Daidzein-rich isoflavone-aglycones for menopausal symptoms. Int J Gynaecol Obstet, 89(1), 65-66.
Rosenbrock, H., Seifert-Klauss, V., Kaspar, S., Busch, R., & Luppa, P. B. (2002). Changes of biochemical bone markers during the menopausal transition. Clin Chem Lab Med, 40(2), 143-151.
Ruiz-Larrea, M. B., Martin, C., Martinez, R., Navarro, R., Lacort, M., & Miller, N. J. (2000). Antioxidant activities of estrogens against aqueous and lipophilic radicals; differences between phenol and catechol estrogens. Chem Phys Lipids, 105(2), 179-188.
Scambia, G., Mango, D., Signorile, P. G., Anselmi Angeli, R. A., Palena, C., Gallo, D., et al. (2000). Clinical effects of a standardized soy extract in postmenopausal women: A pilot study. Menopause, 7(2), 105-111.
Schmitt, E., Dekant, W., & Stopper, H. (2001). Assaying the estrogenicity of phytoestrogens in cells of different estrogen sensitive tissues. Toxicol In Vitro, 15(4-5), 433-439.
Setchell, K. D., Brown, N. M., Desai, P., Zimmer-Nechemias, L., Wolfe, B. E., Brashear, W. T., et al. (2001). Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr, 131(4 Suppl), 1362S-1375S.
Setchell, K. D., Brown, N. M., Zimmer-Nechemias, L., Brashear, W. T., Wolfe, B. E., Kirschner, A. S., et al. (2002a). Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability. Am J Clin Nutr, 76(2), 447-453.
Setchell, K. D., Zimmer-Nechemias, L., Cai, J., & Heubi, J. E. (1997). Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet, 350(9070), 23-27.
Setchell, K. D., Brown, N. M., & Lydeking-Olsen, E. (2002). The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr, 132(12), 3577-3584.

Spence, L. A., Lipscomb, E. R., Cadogan, J., Martin, B., Wastney, M. E., Peacock, M., et al. (2005). The effect of soy protein and soy isoflavones on calcium metabolism in postmenopausal women: A randomized crossover study. Am J Clin Nutr, 81(4), 916-922.
Stumpf, P. G., & Trolice, M. P. (1994). Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am, 21(2), 219-229.
Souberbielle, J. C., Cormier, C., & Kindermans, C. (1999). Bone markers in clinical practice. Curr Opin Rheumatol, 11(4), 312-319.
Stepan, J. J., Pospichal, J., Presl, J., & Pacovsky, V. (1987). Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone, 8(5), 279-284.
Stepan, J. J., Silinkova-Malkova, E., Havranek, T., Formankova, J., Zichova, M., Lachmanova, J., et al. (1983). Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta, 133(2), 189-200.
Sugimoto, E., & Yamaguchi, M. (2000). Anabolic effect of genistein in osteoblastic mc3t3-e1 cells. Int J Mol Med, 5(5), 515-520.
Sugimoto, T., Nishiyama, K., Kuribayashi, F., & Chihara, K. (1997). Serum levels of insulin-like growth factor (igf) i, igf-binding protein (igfbp)-2, and igfbp-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res, 12(8), 1272-1279.
Taylor, A. K., Linkhart, S., Mohan, S., Christenson, R. A., Singer, F. R., & Baylink, D. J. (1990). Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab, 70(2), 467-472.
Tougaard, L. (1973). The degree of mineralization in bone tissue. The phosphorus-hydroxyproline ratio determined on small amounts of bone tissue. Scand J Clin Lab Invest, 32(4), 351-355.
Tikkanen, M. J. (1996). Estrogens, progestins and lipid metabolism. Maturitas, 23 Suppl, S51-55.

Ubelhart, D., Schlemmer, A., Johansen, J. S., Gineyts, E., Christiansen, C., & Delmas, P. D. (1991). Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab, 72(2), 367-373.
Uesugi, S., Watanabe, S., Ishiwata, N., Uehara, M., & Ouchi, K. (2004). Effects of isoflavone supplements on bone metabolic markers and climacteric symptoms in japanese women. Biofactors, 22(1-4), 221-228.
Valtuena, S., Cashman, K., Robins, S. P., Cassidy, A., Kardinaal, A., & Branca, F. (2003). Investigating the role of natural phyto-oestrogens on bone health in postmenopausal women. Br J Nutr, 89 Suppl 1, S87-99.

Vafeiadou, K., Hall, W. L., & Williams, C. M. (2006). Does genotype and equol-production status affect response to isoflavones? Data from a pan-european study on the effects of isoflavones on cardiovascular risk markers in post-menopausal women. Proc Nutr Soc, 65(1), 106-115.
Vermeulen, A. (1976). The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab, 42(2), 247-253.
Wang, X. L., Hur, H. G., Lee, J. H., Kim, K. T., & Kim, S. I. (2005). Enantioselective synthesis of s-equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium. Appl Environ Microbiol, 71(1), 214-219.
Wangen, K. E., Duncan, A. M., Merz-Demlow, B. E., Xu, X., Marcus, R., Phipps, W. R., et al. (2000). Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J Clin Endocrinol Metab, 85(9), 3043-3048.
Watts, N. B. (1999). Clinical utility of biochemical markers of bone remodeling. Clin Chem, 45(8 Pt 2), 1359-1368.
Wu, J., Oka, J., Higuchi, M., Tabata, I., Toda, T., Fujioka, M., et al. (2006). Cooperative effects of isoflavones and exercise on bone and lipid metabolism in postmenopausal japanese women: A randomized placebo-controlled trial. Metabolism, 55(4), 423-433.
Xu, X., Harris, K. S., Wang, H. J., Murphy, P. A., & Hendrich, S. (1995). Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr, 125(9), 2307-2315.
Yang, T. S., Chen, Y. R., Chen, Y. J., Chang, C. Y., & Ng, H. T. (2004). Osteoporosis: Prevalence in taiwanese women. Osteoporos Int, 15(4), 345-347.

Ye, Y. B., Tang, X. Y., Verbruggen, M. A., & Su, Y. X. (2006). (in press). Soy isoflavones attenuate bone loss in early postmenopausal chinese women: A single-blind randomized, placebo-controlled trial. Eur J Nutr.

Yunoki, H., Yagi, H., Nagashima, K., Noji, T., Miyake, H., & Kuroume, T. (1990). N-terminal propeptide of type-iii procollagen concentrations in the cord blood: An index of newborn maturity. Biol Neonate, 58(5), 264-270.